



For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Joji Nakayama, Representative Director, President and CEO  
(Code no.: 4568, First Section, Tokyo Stock Exchange)  
Please address inquiries to Noriaki Ishida Corporate Officer,  
Vice President, Corporate Communications Department  
Telephone: +81-3-6225-1126  
<http://www.daiichisankyo.com>

### **Correction to the Documents for Top Management Presentation**

**TOKYO, Japan (November 5, 2014)** – With regard to the above, we wish to inform that there were typographical errors in the document, which was filed on November 4, 2014 at 11:30, as follows.

#### **Correction**

- (1) Page20 Progress in R&D pipeline CL-108 region  
Page23 Major R&D Pipeline CL-108 region  
Before: US/EU  
After : US
  
- (2) Page20 Progress in R&D pipeline DS-6051 region  
Page23 Major R&D Pipeline DS-6051 region  
Before: JP  
After : US
  
- (3) Page21 CL-108: Hydrocodone combination the second line  
Before: Exclusive license for commercialization in US/EU  
After : Exclusive license for commercialization in US

More information regarding Daiichi Sankyo's FY2014 Q2 financial results can be found at the following link:

[http://www.daiichisankyo.com/media\\_investors/investor\\_relations/quarterly\\_results/index.html](http://www.daiichisankyo.com/media_investors/investor_relations/quarterly_results/index.html)